biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
CG Oncology projects
5 ClinicalTrials.gov programs sponsored by CG Oncology.
CG Oncology has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CG0070
CG Oncology
Bladder Cancer
1 trial -
CG0070
CG Oncology
Non Muscle Invasive Bladder Cancer
1 trial -
Cretostimogene Grenadenorepvec
CG Oncology
High-Risk Non-Muscle-Invasive Bladder Cancer
1 trial -
Ivaltinostat
CG Oncology
Metastatic Pancreatic Adenocarcinoma
1 trial -
oncolytic adenovirus expressing GMCSF
CG Oncology
Bladder Cancer
1 trial
Frequently asked questions
How many clinical projects does CG Oncology have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.